Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

The agency announced on November 2, 2011 that it had approved Edwards Lifesciences' first-generation Sapien TAVR device for patients with severe aortic stenosis who are ineligible for open-heart ...

In particular, research on Edwards' market-leading Sapien TAVR device suggests that the learning curve is 200 cases. That's the inflection point where the physician can deliver optimal patient ...

The UHS Heart & Vascular Institute recently celebrated a significant milestone with the completion of their 1,000th TAVR (Transcatheter Aortic Valve Replacement) procedure. This achievement is ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treati ...